All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
On July 14, 2020, the U.S. Food and Drug Administration (FDA) granted an orphan drug designation for PXS-5505.
Myelofibrosis is a rare hematological disease where bone marrow is gradually replaced by fibrotic tissue eventually leading to bone marrow failure. Patients with myelofibrosis have limited therapeutic options and a poor prognosis. Lysyl oxidases (LOX) are involved in cross-linking extracellular matrix proteins and have been shown to be upregulated in patients with myelofibrosis.1 PXS-5505, a pan-LOX inhibitor, is currently under development for the treatment of myelofibrosis. It is an oral compound that has demonstrated a well-tolerated safety profile, as well as good pharmacokinetic and pharmacodynamic properties in a phase I study. Also, in vivo models have demonstrated significant reductions in fibrotic burden.2
Read here for more information on myelofibrosis.
Management of thrombocytopenia in patients with myelofibrosis
Myelofibrosis (MF) is a progressive disease that can either appear de novo (primary MF [PMF]) or occur following a prior diagnosis of essential thrombocythemia (post-ET MF [PET-MF]) or...
PXS-5505: Investigational New Drug application has been submitted to the FDA
Following the recent U.S. Food and Drug Administration (FDA) orphan drug designation, an Investigational New Drug (IND) application has been submitted for a phase I/II study...
Subscribe to get the best content related to MPN delivered to your inbox